Herzliya, Israel--Israeli pharmaceutical firm InnoCan Pharma has filed a patent for a pain and itch relief technology that uses a blend of magnesium and cannabis. Specializing in developing cannabinoid-based therapies, the company's products aim to enhance drug efficiency while minimizing side effects and reducing medication dosage and treatment frequency.
[Image via NoCamels]
According to a NoCamels report, InnoCan Pharma offers a line of beauty and cosmetic products under the Shir brand in addition to therapeutic solutions. These skincare products incorporate cannabidiol (CBD), known for its potential anti-inflammatory properties and benefits for various skin conditions.
In the report, Iris Bincovich, CEO of InnoCan Pharma, expressed her excitement about the new patent application. “This patent represents the remarkable synergy between our combined magnesium and cannabis topical solution, showcasing a diverse range of cannabinoids and customizable dosages for optimal pain and itching alleviation,” she said, per the report.
In the report, Bincovich emphasized its ongoing commitment to expanding its cannabis-based intellectual property portfolio and pioneering novel therapeutic solutions within the rapidly evolving pharmaceutical technology industry. InnoCan Pharma is based in Herzliya, central Israel.
Learn more in the full NoCamels report.